Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pembrolizumab + CD19 CAR T
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
pembrolizumab + CD19 CAR T (Shanghai Tong Ren Hospital) is a combination immunotherapy regimen being investigated for the treatment of relapsed or refractory B-cell malignancies, including B-cell acute lymphoblastic leukemia and B-cell lymphoma. The regimen consists of pembrolizumab (Keytruda), a humanized monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor to inhibit immune checkpoints, and autologous T cells engineered with a chimeric antigen receptor (CAR) targeting the CD19 antigen. The CAR construct utilized by Shanghai Tong Ren Hospital typically includes an anti-CD19 single-chain variable fragment (scFv) linked to CD3-zeta and CD28 costimulatory signaling domains. By combining these two agents, the therapy aims to leverage the direct tumor-targeting capabilities of CAR T cells while using pembrolizumab to mitigate PD-1-mediated immunosuppression and CAR T-cell exhaustion, potentially improving clinical outcomes in patients with aggressive B-cell cancers.
- Other names
- pembrolizumab + CD19-targeting CAR T cellsKeytruda + CD19 CAR Tpembrolizumab + anti-CD19 CAR-T
02
Targets
CD19 (B lymphocyte antigen CD19)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on pembrolizumab + CD19 CAR T.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pembrolizumab + CD19 CAR T.